Skip to main content
Top
Published in: Tumor Biology 5/2015

01-05-2015 | Research Article

The effect of benzyl isothiocyanate and its computer-aided design derivants targeting alkylglycerone phosphate synthase on the inhibition of human glioma U87MG cell line

Authors: Yu Zhu, Anmin Liu, Xuebin Zhang, Lisha Qi, Ling Zhang, Jing Xue, Yi Liu, Ping Yang

Published in: Tumor Biology | Issue 5/2015

Login to get access

Abstract

Benzyl isothiocyanate (BITC) has been shown to have inhibitory potential for human glioma U87MG cells; however, the effect and mechanism were not fully clear. In the present study, we found that BITC could inhibit U87MG cell proliferation, adhesion, invasion, and vasculogenic mimicry (VM) formation potential and induce oxidative stress, apoptosis, and cell cycle arrest. We also found that the expression of proliferation, invasion, VM oxidative stress, apoptosis, and cell cycle-related gene and the activity of tumor-related signaling pathways, including protein kinase C (PKC) ζ and Akt/nuclear factor-kappa B (NF-κB) pathways, were suppressed by BITC treatment. We also explored the anti-tumor potential of BITC in vivo, and we found that BITC also could regulate the expression of tumor-related gene and angiogenesis in nude mice model. Finally, we optimized the BITC construction targeting alkylglycerone phosphate synthase (AGPS) by computer-aided design, and the derivants also showed anti-tumor potential in vitro.
Literature
1.
go back to reference Walbert T, Chasteen K. Palliative and supportive care for glioma patients. Cancer Treat Res. 2015;163:171–84.CrossRefPubMed Walbert T, Chasteen K. Palliative and supportive care for glioma patients. Cancer Treat Res. 2015;163:171–84.CrossRefPubMed
2.
go back to reference Junes-Gill KS, Lawrence CE, Wheeler CJ, Cordner R, Gill TG, et al. Human hematopoietic signal peptide-containing secreted 1 (hHSS1) modulates genes and pathways in glioma: implications for the regulation of tumorigenicity and angiogenesis. BMC Cancer. 2014;1:920.CrossRef Junes-Gill KS, Lawrence CE, Wheeler CJ, Cordner R, Gill TG, et al. Human hematopoietic signal peptide-containing secreted 1 (hHSS1) modulates genes and pathways in glioma: implications for the regulation of tumorigenicity and angiogenesis. BMC Cancer. 2014;1:920.CrossRef
3.
go back to reference Pastwa E, Poplawski T, Lewandowska U, Somiari SB, Blasiak J, et al. Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells. Int J Biochem Cell Biol. 2014;53:423–31.CrossRefPubMed Pastwa E, Poplawski T, Lewandowska U, Somiari SB, Blasiak J, et al. Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells. Int J Biochem Cell Biol. 2014;53:423–31.CrossRefPubMed
4.
go back to reference Liu HL, Huang CY, Chen JY, Wang HY, Chen PY, et al. Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment. PLoS One. 2014;12:e114311.CrossRef Liu HL, Huang CY, Chen JY, Wang HY, Chen PY, et al. Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment. PLoS One. 2014;12:e114311.CrossRef
5.
go back to reference Xiao Z, Mi L, Chung FL, Veenstra TD. Proteomic analysis of covalent modifications of tubulins by isothiocyanates. J Nutr. 2012;7:1377S–81.CrossRef Xiao Z, Mi L, Chung FL, Veenstra TD. Proteomic analysis of covalent modifications of tubulins by isothiocyanates. J Nutr. 2012;7:1377S–81.CrossRef
6.
go back to reference Zhang Y, Yao S, Li J. Vegetable-derived isothiocyanates: anti-proliferative activity and mechanism of action. Proc Nutr Soc. 2006;65(1):68–75.CrossRefPubMed Zhang Y, Yao S, Li J. Vegetable-derived isothiocyanates: anti-proliferative activity and mechanism of action. Proc Nutr Soc. 2006;65(1):68–75.CrossRefPubMed
7.
go back to reference Wu X, Zhou QH, Xu K. Are isothiocyanates potential anti-cancer drugs? Acta Pharmacol Sin. 2009;5:501–12.CrossRef Wu X, Zhou QH, Xu K. Are isothiocyanates potential anti-cancer drugs? Acta Pharmacol Sin. 2009;5:501–12.CrossRef
8.
go back to reference Yan H, Zhu Y, Liu B, Wu H, Li Y, et al. Mitogen-activated protein kinase mediates the apoptosis of highly metastatic human non-small cell lung cancer cells induced by isothiocyanates. Br J Nutr. 2011;201(12):1779–91.CrossRef Yan H, Zhu Y, Liu B, Wu H, Li Y, et al. Mitogen-activated protein kinase mediates the apoptosis of highly metastatic human non-small cell lung cancer cells induced by isothiocyanates. Br J Nutr. 2011;201(12):1779–91.CrossRef
9.
go back to reference Zhu Y, Zhuang JX, Wang Q, Zhang HY, Yang P. Inhibitory effect of benzyl isothiocyanate on proliferation in vitro of human glioma cells. Asian Pac J Cancer Prev. 2013;4:2607–10.CrossRef Zhu Y, Zhuang JX, Wang Q, Zhang HY, Yang P. Inhibitory effect of benzyl isothiocyanate on proliferation in vitro of human glioma cells. Asian Pac J Cancer Prev. 2013;4:2607–10.CrossRef
10.
go back to reference Francescone R, Scully S, Bentley B, Yan W, Taylor SL, et al. Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem. 2012;29:24821–31.CrossRef Francescone R, Scully S, Bentley B, Yan W, Taylor SL, et al. Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem. 2012;29:24821–31.CrossRef
11.
go back to reference Huang CS, Lin AH, Liu CT, Tsai CW, Chang IS, et al. Isothiocyanates protect against oxidized LDL-induced endothelial dysfunction by upregulating Nrf2-dependent antioxidation and suppressing NFκB activation. Mol Nutr Food Res. 2013;11:1918–30.CrossRef Huang CS, Lin AH, Liu CT, Tsai CW, Chang IS, et al. Isothiocyanates protect against oxidized LDL-induced endothelial dysfunction by upregulating Nrf2-dependent antioxidation and suppressing NFκB activation. Mol Nutr Food Res. 2013;11:1918–30.CrossRef
12.
go back to reference Grzesiak JJ, Smith KC, Burton DW, Deftos LJ, Bouvet M. Integrin-mediated laminin-1 adhesion upregulates CXCR4 and IL-8 expression in pancreatic cancer cells. Surgery. 6:804–814. Grzesiak JJ, Smith KC, Burton DW, Deftos LJ, Bouvet M. Integrin-mediated laminin-1 adhesion upregulates CXCR4 and IL-8 expression in pancreatic cancer cells. Surgery. 6:804–814.
13.
go back to reference Lai KC, Huang AC, Hsu SC, Kuo CL, Yang JS, et al. Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem. 2010;5:2935–42.CrossRef Lai KC, Huang AC, Hsu SC, Kuo CL, Yang JS, et al. Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem. 2010;5:2935–42.CrossRef
14.
go back to reference Chen SC, Kung ML, Hu TH, Chen HY, Wu JC, et al. Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial–mesenchymal transition. J Pathol. 2012;2:158–69.CrossRef Chen SC, Kung ML, Hu TH, Chen HY, Wu JC, et al. Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial–mesenchymal transition. J Pathol. 2012;2:158–69.CrossRef
15.
go back to reference Sehrawat A, Singh SV. Benzyl isothiocyanate inhibits epithelial-mesenchymal transition in cultured and xenografted human breast cancer cells. Cancer Prev Res (Phila). 2011;7:1107–17.CrossRef Sehrawat A, Singh SV. Benzyl isothiocyanate inhibits epithelial-mesenchymal transition in cultured and xenografted human breast cancer cells. Cancer Prev Res (Phila). 2011;7:1107–17.CrossRef
16.
go back to reference Kuruma H, Kamata Y, Takahashi H, Igarashi K, Kimura T, et al. Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer. Am J Pathol. 2009;6:2044–50.CrossRef Kuruma H, Kamata Y, Takahashi H, Igarashi K, Kimura T, et al. Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer. Am J Pathol. 2009;6:2044–50.CrossRef
17.
go back to reference Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;16:5000–5.CrossRef Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;16:5000–5.CrossRef
18.
go back to reference Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, et al. Non-transcriptional control of DNA replication by c-Myc. Nature. 2007;7152:445–51.CrossRef Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, et al. Non-transcriptional control of DNA replication by c-Myc. Nature. 2007;7152:445–51.CrossRef
19.
go back to reference Xiao D, Powolny AA, Singh SV. Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J Biol Chem. 2008;44:30151–63.CrossRef Xiao D, Powolny AA, Singh SV. Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J Biol Chem. 2008;44:30151–63.CrossRef
20.
go back to reference Ho CC, Lai KC, Hsu SC, Kuo CL, Ma CY, et al. Benzyl isothiocyanate (BITC) inhibits migration and invasion of human gastric cancer AGS cells via suppressing ERK signal pathways. Hum Exp Toxicol. 2011;4:296–306.CrossRef Ho CC, Lai KC, Hsu SC, Kuo CL, Ma CY, et al. Benzyl isothiocyanate (BITC) inhibits migration and invasion of human gastric cancer AGS cells via suppressing ERK signal pathways. Hum Exp Toxicol. 2011;4:296–306.CrossRef
21.
go back to reference Misra S, Ghatak S, Vyas A, O’Brien P, Markwald RR, et al. Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer. Med Chem Res. 2014;8:3836–51.CrossRef Misra S, Ghatak S, Vyas A, O’Brien P, Markwald RR, et al. Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer. Med Chem Res. 2014;8:3836–51.CrossRef
22.
go back to reference Yoo BK, Santhekadur PK, Gredler R, Chen D, Emdad L, et al. Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. Hepatology. 2011;5:1538–48.CrossRef Yoo BK, Santhekadur PK, Gredler R, Chen D, Emdad L, et al. Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. Hepatology. 2011;5:1538–48.CrossRef
23.
go back to reference Tsuchiya N, Nakagama H. MicroRNA, SND1, and alterations in translational regulation in colon carcinogenesis. Mutat Res. 2010;1–2:94–100.CrossRef Tsuchiya N, Nakagama H. MicroRNA, SND1, and alterations in translational regulation in colon carcinogenesis. Mutat Res. 2010;1–2:94–100.CrossRef
24.
go back to reference Sun X, Cheng G, Hao M, Zheng J, Zhou X, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010;4:709–22.CrossRef Sun X, Cheng G, Hao M, Zheng J, Zhou X, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010;4:709–22.CrossRef
25.
go back to reference Gorbachev AV, Fairchild RL. Regulation of chemokine expression in the tumor microenvironment. Crit Rev Immunol. 2014;2:103–20.CrossRef Gorbachev AV, Fairchild RL. Regulation of chemokine expression in the tumor microenvironment. Crit Rev Immunol. 2014;2:103–20.CrossRef
26.
go back to reference Wang G, Wang W, Zhou J, Yang X. Correlation between telomerase activity and matrix metalloproteinases 2 expression in gastric cancer. Cancer Biomark. 2013;1:21–8.CrossRef Wang G, Wang W, Zhou J, Yang X. Correlation between telomerase activity and matrix metalloproteinases 2 expression in gastric cancer. Cancer Biomark. 2013;1:21–8.CrossRef
27.
go back to reference Buseman CM, Wright WE, Shay JW. Is telomerase a viable target in cancer? Mutat Res. 2012;1–2:90–7.CrossRef Buseman CM, Wright WE, Shay JW. Is telomerase a viable target in cancer? Mutat Res. 2012;1–2:90–7.CrossRef
28.
go back to reference Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, et al. Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity. Proc Natl Acad Sci U S A. 2013;37:14912–7.CrossRef Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, et al. Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity. Proc Natl Acad Sci U S A. 2013;37:14912–7.CrossRef
29.
go back to reference Liu Z, Wang LE, Strom SS, Spitz MR, Babaian RJ, et al. Overexpression of hMTH in peripheral lymphocytes and risk of prostate cancer: a case-control analysis. Mol Carcinog. 2003;3:123–9.CrossRef Liu Z, Wang LE, Strom SS, Spitz MR, Babaian RJ, et al. Overexpression of hMTH in peripheral lymphocytes and risk of prostate cancer: a case-control analysis. Mol Carcinog. 2003;3:123–9.CrossRef
30.
go back to reference Cho WC, Chow AS, Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol. 2011;1:125–31.CrossRef Cho WC, Chow AS, Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol. 2011;1:125–31.CrossRef
31.
go back to reference Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;6:320–8.CrossRef Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;6:320–8.CrossRef
32.
go back to reference Goschzik T, Gessi M, Denkhaus D, Pietsch T. PTEN mutations and activation of the PI3K/Akt/mTOR signaling pathway in papillary tumors of the pineal region. J Neuropathol Exp Neurol. 2014;8:747–51.CrossRef Goschzik T, Gessi M, Denkhaus D, Pietsch T. PTEN mutations and activation of the PI3K/Akt/mTOR signaling pathway in papillary tumors of the pineal region. J Neuropathol Exp Neurol. 2014;8:747–51.CrossRef
33.
go back to reference Khan MA, Chen HC, Zhang D, Fu J. Twist: a molecular target in cancer therapeutics. Tumour Biol. 2013;5:2497–506.CrossRef Khan MA, Chen HC, Zhang D, Fu J. Twist: a molecular target in cancer therapeutics. Tumour Biol. 2013;5:2497–506.CrossRef
34.
go back to reference Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer. 2010;4:639–44.CrossRef Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer. 2010;4:639–44.CrossRef
35.
go back to reference Shen J, Niu W, Zhou M, Zhang H, Ma J, et al. MicroRNA-410 suppresses migration and invasion by targeting MDM2 in gastric cancer. PLoS One. 2014;8:e104510.CrossRef Shen J, Niu W, Zhou M, Zhang H, Ma J, et al. MicroRNA-410 suppresses migration and invasion by targeting MDM2 in gastric cancer. PLoS One. 2014;8:e104510.CrossRef
36.
go back to reference Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology. 2010;2:545–56.CrossRef Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology. 2010;2:545–56.CrossRef
Metadata
Title
The effect of benzyl isothiocyanate and its computer-aided design derivants targeting alkylglycerone phosphate synthase on the inhibition of human glioma U87MG cell line
Authors
Yu Zhu
Anmin Liu
Xuebin Zhang
Lisha Qi
Ling Zhang
Jing Xue
Yi Liu
Ping Yang
Publication date
01-05-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2986-6

Other articles of this Issue 5/2015

Tumor Biology 5/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine